{"drugs":["Photofrin","Porfimer Sodium"],"mono":{"0":{"id":"923555-s-0","title":"Generic Names","mono":"Porfimer Sodium"},"1":{"id":"923555-s-1","title":"Dosing and Indications","sub":{"0":{"id":"923555-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Barrett's esophagus, Ablation of high-grade dysplasia in patients not undergoing surgery:<\/b> 2 mg\/kg IV over 3 to 5 minutes followed by local application of laser light (630 nanometers wavelength) to the tumor 40 to 50 hours later; a second laser light application may be given 96 to 120 hours after administration of porfimer; patients may receive an additional course a minimum of 90 days after therapy; MAX number of courses is 3 (each separated by 90 days)<\/li><li><b>Barrett's esophagus, Ablation of high-grade dysplasia in patients not undergoing surgery:<\/b> The manufacturer recommends a light dose of 130 Joules\/centimeter;  acceptable light intensity for the balloon\/diffuser combinations are 200 to 270 milliwatts\/centimeter of diffuser. If repeated, use a light dose of 50 Joules\/centimeter of fiber optic diffuser length 96 to 120 hours after initial injection.<\/li><li><b>Carcinoma of esophagus, Completely or partially obstructed disease in patients ineligible for Nd\/YAG laser therapy (palliative):<\/b> 2 mg\/kg IV over 3-5 minutes followed by local application of laser light (630 nanometers wavelength) to the tumor 40 to 50 hours later.  A second laser light application may be given 96 to 120 hours after administration of porfimer, preceded by careful debridement of residual tumor; patients may receive an additional course a minimum of 30 days after therapy; max. number of courses is 3 (each separated by 30 days)<\/li><li><b>Carcinoma of esophagus, Completely or partially obstructed disease in patients ineligible for Nd\/YAG laser therapy (palliative):<\/b> The manufacturer recommends 300 Joules\/centimeter (J\/cm) of tumor length with the fiber tip set to deliver the light dose using exposure times of 12 minutes and 30 seconds<\/li><li><b>Cholangiocarcinoma of biliary tract, Unresectable, after double stenting:<\/b> 2 mg\/kg IV administered 48 hours before laser activation was used in a clinical trial;  photoactivation was performed at 630 nanometers using a light dose of 180 joules\/cm(2)<\/li><li><b>Non-small cell lung cancer, Completely or partially obstructing endobronchial disease:<\/b> 2 mg\/kg IV over 3 to 5 minutes followed by local application of laser light (630 nanometers wavelength) to the tumor 40 to 50 hours later; a second laser light application may be given 96 to 120 hours after administration of porfimer, preceded by careful debridement of residual tumor; patients may receive an additional course a minimum of 30 days after therapy; MAX number of courses is 3 (each separated by 30 days)<\/li><li><b>Non-small cell lung cancer, Microinvasive endobronchial disease; in patients ineligible for surgery or radiotherapy:<\/b> 2 mg\/kg IV over 3 to 5 minutes followed by local application of laser light (630 nanometers wavelength) to the tumor 40 to 50 hours later; a second laser light application may be given 96 to 120 hours after administration of porfimer, preceded by careful debridement of residual tumor; patients may receive an additional course a minimum of 30 days after therapy; MAX number of courses is 3 (each separated by 30 days)<\/li><li><b>Non-small cell lung cancer, Microinvasive endobronchial disease; in patients ineligible for surgery or radiotherapy:<\/b> The manufacturer recommends 200 Joules\/centimeter (J\/cm) of tumor length for both palliation and treatment; with the fiber tip set to deliver the light dose using exposure times of 8 minutes and 20 seconds<\/li><\/ul>"},"1":{"id":"923555-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness have not been established "},"3":{"id":"923555-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Barrett's esophagus, Ablation of high-grade dysplasia in patients not undergoing surgery<\/li><li>Carcinoma of esophagus, Completely or partially obstructed disease in patients ineligible for Nd\/YAG laser therapy (palliative)<\/li><li>Non-small cell lung cancer, Completely or partially obstructing endobronchial disease<\/li><li>Non-small cell lung cancer, Microinvasive endobronchial disease; in patients ineligible for surgery or radiotherapy<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Basal cell carcinoma of skin<\/li><li>Cholangiocarcinoma of biliary tract, Unresectable, after double stenting<\/li><li>Kaposi's sarcoma<\/li><li>Malignant tumor of oral cavity<\/li><li>Malignant tumor of rectum<\/li><li>Non-small cell lung cancer; Diagnosis<\/li><li>Primary malignant neoplasm of urinary system<\/li><\/ul>"}}},"3":{"id":"923555-s-3","title":"Contraindications\/Warnings","sub":[{"id":"923555-s-3-9","title":"Contraindications","mono":"<ul><li>bronchoesophageal or tracheoesophageal fistula, existing<\/li><li>emergency treatment of severe acute respiratory distress due to an obstructing endobronchial lesion<\/li><li>esophageal or gastric varices<\/li><li>esophageal ulcers greater than 1 cm in diameter<\/li><li>porphyria<\/li><li>tumors eroding into a major blood vessel<\/li><\/ul>"},{"id":"923555-s-3-10","title":"Precautions","mono":"<ul><li>abnormal epithelium or cancer beneath new squamous cell epithelium following photodynamic therapy may occur in patients with high-grade dysplasia in Barrett's esophagus; monitoring with endoscopic biopsy recommended<\/li><li>endobronchial tumors in locations which could block the main airway due to treatment-induced inflammation (eg, long or circumferential tracheal tumors, carina tumors that involve both mainstem bronchi circumferentially, or circumferential tumors in the mainstem bronchus in patients with prior pneumonectomy)<\/li><li>esophageal strictures requiring dilation have been reported; possible increased risk in patients who received a nodule pretreatment or had a mucosal segment retreatment<\/li><li>esophageal tumors eroding into the bronchial tree or wall or the trachea; risk of tracheoesophageal or bronchoesophageal fistula<\/li><li>fatal massive hemoptysis (FMH) has been reported; increased risk in patients with large, centrally located tumors, cavitating tumors, or extensive tumors extrinsic to the bronchus<\/li><li>gastrointestinal and esophageal necrosis and perforation, serious and potentially fatal, may occur<\/li><li>hepatic impairment, mild to severe; increased risk of toxicity (eg, photosensitivity lasting longer than 90 days) due to prolonged elimination<\/li><li>ocular sensitivity to sun, bright lights, or car headlights may occur for up to 30 days or longer after treatment<\/li><li>photosensitivity, prolonged (for up to 90 days or more), may occur<\/li><li>radiotherapy; allow 2 to 4 weeks between administering photodynamic therapy and radiotherapy<\/li><li>renal impairment, severe; increased risk of toxicity (eg, photosensitivity lasting longer than 90 days) due to prolonged elimination<\/li><li>respiratory distress due to airway obstruction from inflammation mucositis and necrotic debris may occur between laser light therapy and debridement bronchoscopy in patients with endobronchial tumors; monitoring recommended<\/li><li>thromboembolism has been reported; most cases were in patients with concomitant risk factors (eg, advanced cancer, after major surgery, prolonged immobilization, or cardiovascular disease)<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"923555-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"923555-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"923555-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Abdominal pain (20%), Constipation (11% to 24%), Dysphagia (10% to 22%), Esophageal stricture (32% to 37%), Nausea (24% to 26%), Vomiting (17% to 29%)<\/li><li><b>Hematologic:<\/b>Anemia (32%)<\/li><li><b>Musculoskeletal:<\/b>Backache (11%)<\/li><li><b>Neurologic:<\/b>Insomnia (14%)<\/li><li><b>Respiratory:<\/b>Bronchitis (10%), Dyspnea (7% to 30%), Obstruction of bronchus (21%), Pharyngitis (11%), Stenosis of bronchus (11%)<\/li><li><b>Other:<\/b>Fever (8% to 31%), Pain (22%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Atrial fibrillation (10%), Chest pain (22% to 29%), Chest pain, Substernal (5%), Heart failure (7%), Tachycardia (6%)<\/li><li><b>Dermatologic:<\/b>Photosensitivity (19% to 47%)<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal necrosis, Gastrointestinal perforation<\/li><li><b>Hematologic:<\/b>Thromboembolic disorder<\/li><li><b>Respiratory:<\/b>Hemoptysis (16%), Hemoptysis, Fatal massive (1% to 21%), Pleural effusion (10% to 32%), Pneumonia (12% to 18%), Respiratory distress, Respiratory insufficiency (6% to 10%)<\/li><\/ul>"},"6":{"id":"923555-s-6","title":"Drug Name Info","sub":{"0":{"id":"923555-s-6-17","title":"US Trade Names","mono":"Photofrin<br\/>"},"2":{"id":"923555-s-6-19","title":"Class","mono":"Antineoplastic Agent<br\/>"},"3":{"id":"923555-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"923555-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"923555-s-7","title":"Mechanism Of Action","mono":"Porfimer sodium, a photosensitizing agent for photodynamic therapy (PDT) of tumors and of high-grade dysplasia (HGD) in Barrett's esophagus (BE), exhibits cytotoxic and antitumor actions which are light and oxygen dependent. Tumors, skin, and organs of the reticuloendothelial system retain porfimer sodium and laser light during phototherapy; thus retention selectively targets the tumors. A porphyrin excited state is formed and radical reactions form superoxide and hydroxyl radicals which causes cellular damage.<br\/>"},"8":{"id":"923555-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"923555-s-8-24","title":"Distribution","mono":"Protein binding: approximately 90% <br\/>"},"3":{"id":"923555-s-8-26","title":"Excretion","mono":"Dialyzable: no (hemodialysis) <br\/>"},"4":{"id":"923555-s-8-27","title":"Elimination Half Life","mono":"<ul><li>First dose, 410 hours<\/li><li>Second dose, 725 hours<\/li><\/ul>"}}},"9":{"id":"923555-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>reconstitute vial with 31.8 mL of D5W or NS to yield final concentration of 2.5 mg\/mL; shake well, protect from bright light, and use immediately<\/li><li>administer as a single slow IV injection over 3 to 5 min<\/li><li>avoid extravasation; if it occurs, protect area from light<\/li><li>use proper procedures for handling (gloves and eye protection<\/li><\/ul>"},"10":{"id":"923555-s-10","title":"Monitoring","mono":"<ul><li>endoscopic biopsy in patients with high-grade dysplasia in Barrett's esophagus performed every 3 months, until 4 consecutive negative results; further follow-up every 6 to 12 months<\/li><li>evidence of tumor response, improvement of pulmonary symptoms, achievement of normal swallowing<\/li><li>possibility of tumor erosion into a major blood vessel, e.g. a pulmonary blood vessel, and esophageal varices<\/li><li>respiratory distress; in patients with endobronchial lesions between the laser light therapy and the debridement bronchoscopy<\/li><li>presence of a tracheoesophageal or bronchoesophageal fistula prior to each treatment in esophageal cancer patients<\/li><\/ul>"},"11":{"id":"923555-s-11","title":"How Supplied","mono":"<b>Photofrin<\/b><br\/>Intravenous Powder for Solution: 75 MG<br\/>"},"12":{"id":"923555-s-12","title":"Toxicology","sub":[{"id":"923555-s-12-31","title":"Clinical Effects","mono":"<b>PORFIMER<\/b><br\/>OVERDOSE: No overdose data available. Overdose effects are expected to be an extension of adverse effects reported with therapeutic use. Effects on the duration of photosensitivity from overdose are unknown. ADVERSE EFFECTS: Systemic effects from porfimer injection mainly consist of photosensitivity and mild constipation. Photosensitivity reactions are generally mild to moderate (grade I or  II) and include erythema, swelling, itching, burning sensation, or blisters. The reactions are related to varying degrees of exposure to sunlight and may persist for several weeks. Other adverse effects reported from a study involving patients with obstructing esophageal cancer are as follows: gastrointestinal related (abdominal pain, nausea, vomiting, hematemesis, diarrhea, dyspepsia, dysphagia, esophageal edema and stricture), cardiovascular (chest pain, hypertension, hypotension, atrial fibrillation, tachycardia), respiratory (pleural effusion, dyspnea, pneumonia, pharyngitis), central nervous effects (anxiety, confusion, and insomnia) and anemia. Fever has also been reported in patients receiving porfimer <br\/>"},{"id":"923555-s-12-32","title":"Treatment","mono":"<b>PORFIMER<\/b><br\/><ul><li>Decontamination: Administered intravenously; ingestion is unlikely. Wash exposed skin thoroughly. Irrigate eyes after splash exposure.<\/li><li>Support: Treatment is symptomatic and supportive.<\/li><li>General treatment: Protect eyes and skin from direct sunlight for at least 30 days after overdose.<\/li><li>Myelosuppression: Administer colony stimulating factor. Filgrastim 5 mcg\/kg\/day subQ or IV over 15 to 30 minutes. Sargramostim - Usual dose is 250 mcg\/m(2)\/day infused IV over 4 hours.<\/li><li>Hemodialysis: Porfimer is NOT dialyzable.<\/li><li>Monitoring of patient: Monitor vital signs including temperature and blood pressure. Monitor CBC with differential, platelet count, and fluid and electrolyte status.<\/li><\/ul>"},{"id":"923555-s-12-33","title":"Range of Toxicity","mono":"<b>PORFIMER<\/b><br\/>TOXICITY - Range of toxicity is not well described. Toxicity data are from higher than recommended dosing regimens. Two doses of 2 mg\/kg given 2 days apart in 10 patients and 3 doses of 2 mg\/kg given within 2 weeks in 1 patient were well tolerated with no reported adverse effects. THERAPEUTIC - 2 mg\/kg IV over 3 to 5 minutes used in conjunction with photodynamic therapy. If additional therapy needed, each injection should be separated by a minimum of 90 days. <br\/>"}]},"13":{"id":"923555-s-13","title":"Clinical Teaching","mono":"<ul><li>Warn patient that drug causes photosensitivity and may cause ocular sensitivity for 30 to 90 days after dose.<\/li><li>Advise patient to avoid direct sunlight and bright indoor lighting (eg, examination\/dental\/operating room lamps, unshaded light bulbs at close proximity). Sunscreen will not protect the skin. Patient should wear a hat, dark sunglasses, and protective clothing when outdoors.<\/li><li>Encourage patient to expose skin to ambient indoor light to gradually inactivate remaining drug in skin via a photobleaching reaction.<\/li><li>Drug may cause abdominal pain, constipation, dysphagia, cough, nausea, vomiting, pyrexia, and anemia.<\/li><li>Advise patient to report ocular sensitivity, chest pain, or signs\/symptoms of esophageal stricture or respiratory distress.<\/li><li>Instruct patient that drug is effective only when given in combination with laser therapy. Laser therapy is given 40 to 50 hours after drug administration, and a second laser therapy may be administered 96 to 120 hours after drug administration.<\/li><li>Advise patient that more than one treatment may be needed. Patients with cancer must wait at least 30 days between treatments; patients with Barrett's esophagus must wait at least 90 days between treatments.<\/li><\/ul>"}}}